PharmaCorp Rx Inc. (TSXV:PCRX)
Canada · Delayed Price · Currency is CAD 0.4000
0.00 (0.00%)
Oct 20, 2026, 3:58 PM EST
PharmaCorp Rx Stock Forecast
Stock Price Forecast
According to 3 analysts polled by S&P Global, PharmaCorp Rx stock has a consensus rating of "Buy" and an average price target of $0.67. The average 1-year stock price forecast is 67.50% higher than the current stock price, while the lowest is $0.60 (+50.00%) and the highest is $0.70 (+75.00%).
Price Target: $0.67 (+67.50%)
Analyst Consensus: Buy
Price Target
Chart* Price targets were last updated on Jun 2, 2026.
Analyst Ratings
The average analyst rating for PharmaCorp Rx stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '26 | May '26 | Jun '26 | Jul '26 | Aug '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 2 | 2 | 2 | 1 |
| Buy | 0 | 0 | 1 | 1 | 1 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Raymond James No rating | Raymond James | Buy Initiates $0.70 | Buy | Initiates | $0.70 | +75.00% | Jun 2, 2026 |
Financial Forecast
Revenue This Year
49.96M
from 20.89M
Increased by 139.11%
Revenue Next Year
95.97M
from 49.96M
Increased by 92.09%
EPS This Year
0.01
from -0.01
EPS Next Year
0.02
from 0.01
Increased by 133.30%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is CAD.